Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
CATAPRES / clonidine oral
Generic name / active ingredient
clonidine hydrochloride immediate-release tablets
Dosage-form class
Clonidine hydrochloride immediate-release oral tablets. Products outside this package identity include CATAPRES-TTS transdermal systems, DURACLON injection, KAPVAY/JENLOGA/NEXICLON XR extended-release products, JAVADIN oral solution, the COMBIPRES fixed combination and other clonidine-containing products. A shared generic name or milligram figure does not establish formulation conversion, frequency, tapering, splitting or substitution.
Route
Oral
Record reviewed
2026-09-02

Copy from the pack in hand

Source-linked reading points

  • Somnolence, sedation, fatigue, dizziness, dry mouth and constipation are common. Older adults, night-time rising or co-use of sedating/blood-pressure medicines requires priority review of alertness, gait, orthostatic pressure and falls. Severe somnolence, fainting, injury or altered awareness needs local emergency care.
  • Bradycardia, conduction abnormalities and hypotension require review with pulse, symptoms and the complete medicine list. If a beta blocker, digoxin, verapamil, diltiazem or another heart-rate/blood-pressure medicine is also present, do not self-space, adjust or choose one to stop first.
  • Abrupt clonidine withdrawal can cause a rapid pressure rise, headache, nervousness or agitation and tremor; rare severe events can be life-threatening. Risk needs particular attention at higher doses or with a beta blocker. Do not abruptly stop from a webpage or ask it to generate a taper schedule.
  • Vomiting, inability to eat or drink, missed medicine, hospital admission, surgery or an empty pack requires prompt contact with the prescriber or pharmacist about continuity. The site cannot calculate catch-up use, a substitute formulation or a temporary plan.

Reviewed presentation examples — compare every field

  • 0.05 mg clonidine hydrochloride per tablet; 100-tablet bottleNDC 52817-183-10
  • 0.1 mg clonidine hydrochloride per tablet; 100-tablet bottleNDC 52817-180-10
  • 0.1 mg clonidine hydrochloride per tablet; 500-tablet bottleNDC 52817-180-50
  • 0.1 mg clonidine hydrochloride per tablet; 1000-tablet bottleNDC 52817-180-00
  • 0.2 mg clonidine hydrochloride per tablet; 100-tablet bottleNDC 52817-181-10
  • 0.2 mg clonidine hydrochloride per tablet; 500-tablet bottleNDC 52817-181-50
  • 0.2 mg clonidine hydrochloride per tablet; 1000-tablet bottleNDC 52817-181-00
  • 0.3 mg clonidine hydrochloride per tablet; 100-tablet bottleNDC 52817-182-10

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-09-02
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image